drugset / Trial / NCT02172352

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT02172352

Phase 2 Completed 28 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate the dose response following single inhalation of Ba 679 BR inhalation powder in COPD patients using pulmonary functions as indicators, and to compare data obtained with overseas study findings

Timeline

Start
1998-07
Primary completion
1999-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified Inhaled